World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
152
Citations
80642
World Ranking
1084
National Ranking
622

Jerry Avorn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jerry Avorn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 702 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jerry Avorn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jerry Avorn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 152 D-Index — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jerry Avorn is affiliated with Brigham and Women's Hospital in the United States and specializes primarily in Medicine and Economics, Econometrics and Finance. Their research covers multiple subfields including Economics and Econometrics, Infectious Diseases, Pulmonary and Respiratory Medicine, Physiology, and Statistics and Probability.

Avorn's recent publications illustrate a focus on pharmaceutical regulation and public health, particularly in the context of the COVID-19 pandemic. Notable papers include:

  • FDA Approval and Regulation of Pharmaceuticals, 1983-2018 (2020) published in JAMA
  • Drug Evaluation during the Covid-19 Pandemic (2020) published in New England Journal of Medicine
  • FDA Regulation and Approval of Medical Devices: 1976-2020 (2021) published in JAMA
  • US public investment in development of mRNA covid-19 vaccines: retrospective cohort study (2023) published in BMJ
  • An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19 (2020) published in Health Affairs

The research topics they engage with include Health Systems, Economic Evaluations, Quality of Life; Pharmaceutical Economics and Policy; Pharmaceutical industry and healthcare; Pharmaceutical studies and practices; SARS-CoV-2 and COVID-19 Research; Biomedical Ethics and Regulation; and Statistical Methods in Clinical Trials.

Among frequent coauthors collaborating with Avorn are Aaron S. Kesselheim, Jonathan J. Darrow, Benjamin N. Rome, William B. Feldman, and Til Stürmer. These collaborations reflect a network around shared interests in healthcare policy, pharmaceutical research, and clinical regulation.

Avorn's work is regularly published in venues such as UNC Libraries, JAMA Network Open, New England Journal of Medicine, JAMA, and JAMA Internal Medicine. These journals reflect a broad engagement with medical research, policy, and clinical practice audiences.

Best Publications

  • Variable Selection for Propensity Score Models

    M. Alan Brookhart;Sebastian Schneeweiss;Kenneth J. Rothman;Kenneth J. Rothman;Robert J. Glynn

  • Long-term persistence in use of statin therapy in elderly patients☆

    J.S. Benner;R.J. Glynn;H. Mogun;P.J. Neumann

  • A review of uses of health care utilization databases for epidemiologic research on therapeutics

    Sebastian Schneeweiss;Jerry Avorn

  • Principles of educational outreach ('academic detailing') to improve clinical decision making.

    Stephen Bertram Soumerai;Jerry Lewis Avorn

  • Improving Drug-Therapy Decisions through Educational Outreach

    Jerry Lewis Avorn;Stephen Bertram Soumerai

  • Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications

    Philip S. Wang;Sebastian Schneeweiss;Jerry Avorn;Michael A. Fischer

  • High-dimensional propensity score adjustment in studies of treatment effects using health care claims data

    Sebastian Schneeweiss;Jeremy A. Rassen;Robert J. Glynn;Jerry Avorn

  • Self-management education programs in chronic disease: a systematic review and methodological critique of the literature.

    Asra Warsi;Philip S. Wang;Michael P. LaValley;Jerry Avorn

  • A combined comorbidity score predicted mortality in elderly patients better than existing scores

    Joshua J. Gagne;Robert J. Glynn;Jerry Avorn;Raisa Levin

  • Scientific versus commercial sources of influence on the prescribing behavior of physicians

    Jerry Avorn;Milton Chen;Robert Hartley

  • Reduction of bacteriuria and pyuria after ingestion of cranberry juice.

    Jerry Avorn;Mark Monane;Jerry H. Gurwitz;Robert J. Glynn

  • Incidence and preventability of adverse drug events in nursing homes.

    Jerry H. Gurwitz;Terry S. Field;Jerry Avorn;Jerry Avorn;Danny McCormick

  • Persistence of Use of Lipid-Lowering Medications: A Cross-National Study

    Jerry Avorn;Johanne Monette;Anne Lacour;Rhonda L. Bohn

  • Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data

    Sebastian Schneeweiss;John D. Seeger;Malcolm Maclure;Philip S. Wang

  • Adherence to Therapy With Oral Antineoplastic Agents

    Ann H. Partridge;Jerry Avorn;Philip S. Wang;Eric P. Winer

  • Full coverage for preventive medications after myocardial infarction

    Niteesh K. Choudhry;Jerry Avorn;Robert J. Glynn;Elliott M. Antman

  • Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer

    Ann H. Partridge;Philip S. Wang;Eric P. Winer;Jerry Avorn

  • The exclusion of the elderly and women from clinical trials in acute myocardial infarction.

    Jerry H. Gurwitz;Nananda F. Col;Jerry Avorn

  • Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

    Stephen Bertram Soumerai;Dennis Ross-Degnan;Jerry Lewis Avorn;Thomas J. McLaughlin

  • A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

    Til Stürmer;Manisha Joshi;Robert J. Glynn;Jerry Avorn

Frequent Co-Authors

Robert J. Glynn
Robert J. Glynn Harvard Medical School
Sebastian Schneeweiss
Sebastian Schneeweiss Brigham and Women's Hospital
Daniel H. Solomon
Daniel H. Solomon Brigham and Women's Hospital
Jerry H. Gurwitz
Jerry H. Gurwitz University of Massachusetts Chan Medical School
Niteesh K. Choudhry
Niteesh K. Choudhry Brigham and Women's Hospital
William H. Shrank
William H. Shrank Humana (United States)
Philip S. Wang
Philip S. Wang Harvard Medical School
Kenneth J. Rothman
Kenneth J. Rothman Boston University
Stephen B. Soumerai
Stephen B. Soumerai Harvard University
M. Alan Brookhart
M. Alan Brookhart University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA doesn’t just mean medical school. Many healthcare professionals begin with practical, online degree options that are flexible and career-oriented. For registered nurses looking to advance their credentials, an online rn to bsn no clinicals program offers an accessible way to earn a bachelor’s degree without the need for traditional in-person clinicals.

Those interested in fast-tracking their careers might consider a 6 month lpn program online, providing a rapid pathway to becoming a licensed practical nurse. For nurses aiming for the highest level of clinical practice, several options are available. The fastest dnp online program allows for completion in a reduced timeframe, while the easiest dnp program online helps identify the most flexible and manageable Doctor of Nursing Practice programs available.

By exploring these alternative and accelerated educational pathways, students and professionals can advance their healthcare careers while balancing work and life commitments.

Best Scientists Citing Jerry Avorn

Trending Scientists

Recently Published Articles